// App-Quantinova.ai

650 : Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial

Researchers

Presenter

  • Jorge Cortes

Principal Investigators

  • Javier Pinilla-Ibarz

  • Daniel J DeAngelo

  • Elisabetta Abruzzese

  • Delphine Rea

  • Michele Baccarani

  • Martin C. Muller

  • Carlo Gambacorti-Passerini

  • Stephanie Lustgarten

  • Victor M. Rivera

  • Tim Clackson

  • Christopher D. Turner

  • Philipp D le Coutre

  • Frank G. Haluska

  • Francois Guilhot

  • Michael W. Deininger

  • Andreas Hochhaus

  • Timothy P. Hughes

  • John M Goldman

  • Neil P. Shah

  • Hagop M. Kantarjian

  • Ronald Paquette

  • Charles Chuah

  • Franck E. Nicolini

  • Jane F Apperley

  • H. Jean Khoury

  • Moshe Talpaz

  • John F. DiPersio

Medical Centers

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Urologische Klinik Universitatsmedizin Mannheim, Mannheim, Germany

  • Universitatsklinikum Jena, Jena, Germany

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Dana-Farber Cancer Institute, Boston, MA

  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

  • Centre for Haematology, Imperial Collegel, London, United Kingdom

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Hematology-Oncology L. and A. Seragnoli, S Orsola-Malpighi University Hospital, Bologna, Italy

  • Washington University School of Medicine, St. Louis, MO

  • Inserm CIC 1402, CHU de Poitiers, University Hospital, Poitiers, France

  • Hematologie Adultes, Hopital Saint-Louis, Paris, France

  • Ronald Reagan UCLA Medical Center, University of California, Los Angeles, CA

  • University of California, San Francisco, CA

  • Comprehensive Cancer Center, University of Michigan, Grass Lake, MI

  • Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore, Singapore

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia

  • Unita di Ricerca Clinica - Ematologia, Azienda Ospedaliera San Gerardo/University of Milano Bicocca, Monza, Italy

  • Centre for Haematology, Imperial Collegel, London, United Kingdom

  • S Eugenio Hospital, Tor Vergata University, Rome, Italy,

  • Medizinische Klinik m.S., Hamatologie, Onkologie und Tumorimmunologie, Charite, Universitatsmedizin Berlin, Berlin, Germany

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • Italy

  • Singapore

  • Germany

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • ARIAD Pharmaceutical

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Thrombocytopenia

  • Pancreatitis

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved